Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Valeant Hires Attorney, Crisis Management Firm as U.S. Scrutiny Mounts

Sarah N. Lynch & David Ingram  |  

“Valeant uses a variety of firms for legal and public relations work. Covington recently was retained to assist the company in responding to congressional inquiries,” Laurie Little, the senior vice president of investor relations, says in a statement.

According to a July 2015 survey sponsored by the Public Affairs Council, 64% of Americans say a company’s honesty and responsiveness in dealing with a crisis is the most important factor when deciding whether to buy from that company in the future.

ADVERTISEMENT
SCROLL TO CONTINUE

The survey also found that the pharmaceutical industry was deemed the least trustworthy sector.

Related Articles
    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies

    NEW YORK/LOS ANGELES (Reuters)—In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for…

    Newly Released Documents Show Profit-Seeking Behind Price Hikes at Turing, Valeant

    WASHINGTON/NEW YORK (Reuters)—A decision by Turing Pharmaceuticals to raise the price of a lifesaving drug by 5,000% drove up some patient co-pays to as high as $16,000, according to excerpts of documents that congressional committee members released on Tuesday. The excerpts, which are highlighted in memos released by Democrats on the powerful U.S. House of…

    Valeant Prices Psoriasis Treatment at $3,500 Per Month

    (Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEDrugmakers are…